<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03795571</url>
  </required_header>
  <id_info>
    <org_study_id>R2-GOD regimen</org_study_id>
    <nct_id>NCT03795571</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL</brief_title>
  <acronym>R2-GOD</acronym>
  <official_title>Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous study showed that Lenalidomide or R-GDP could achieve response in Relapse and
      Refractory DLBCL.The investigators therefore design this phase I study to investigate the
      safety and efficacy of R2-GOD in relapsed diffuse large-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose and dose limited toxicity</measure>
    <time_frame>28 days after first cycle of R2-GOD regimen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate,</measure>
    <time_frame>6 months</time_frame>
    <description>overall response rate after treated by R-GemOx or R-miniCHOP overall response rate after treated by R2-GOD regimen regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any causePFS：from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diffuse Large B-cell Lymphoma Recurrent</condition>
  <condition>Diffuse Large B Cell Lymphoma Refractory</condition>
  <arm_group>
    <arm_group_label>R2-GOD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375mg/m2，d0</description>
    <arm_group_label>R2-GOD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2，d1，d5</description>
    <arm_group_label>R2-GOD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 75mg/m2，d1</description>
    <arm_group_label>R2-GOD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40mg/d，d1~d4</description>
    <arm_group_label>R2-GOD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide Oral Capsule</intervention_name>
    <description>Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1~d10； 21days a cycle</description>
    <arm_group_label>R2-GOD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years old;

          -  ECOG PS 0- 2;

          -  Histologically confirmed diffuse large B cell lymphoma（With exception of Primary
             mediastinal large B cell lymphoma、Primary central nervous system lymphoma、HIV-related
             lymphoma),relapse or refractory,defined as:

               -  relapse after standard first-line immunochemotherapy( R-CHOP or R-CHOP like)

               -  SD as best response after 4 cycles or PD after 2 cycles of first-line
                  immunochemotherapy;

          -  a measurable or evaluable disease at the time of enrollment(diameter ≥ 1.5cm）；

          -  Eligible for subsequent autologous stem cell transplantation；

          -  Female subjects in childbearing age, their serum or urine pregnancy test must be
             negative. All patients must agree to take effective contraceptive measures during the
             trial measures

          -  Expected survival ≥ 12 weeks；

          -  Understand and voluntarily sign an informed consent form, able to adhere to the study
             visit schedule and other protocol requirements

        Exclusion Criteria:

          -  Women who are pregnant or lactating. Patients have breeding intent in 12 months or
             cannot take effective contraceptive measures during the trial measures；

          -  Uncontrollable active infection within four week. Prophylactic antibiotic, antiviral
             and antifungal treatment is permissible. Active hepatitis B or hepatitis C virus
             infection, as well as acquired, congenital immune deficiency diseases, including but
             not limited to HIV-infected persons；

          -  Used of systemic anti-tumor treatment within four weeks；

          -  CNS or meningeal involvement;

          -  Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than
             two fold of upper normal level,Ccr＜ 50 mL/min unless these abnormalities were related
             to the lymphoma;

          -  Poor bone-marrow reserve, defined as neutrophil count less than 1.5×10⁹/L or platelet
             count less than 75×10⁹/L, unless caused by bone marrow infiltration;

          -  New York Heart Association class III or IV cardiac failure; or Ejection fraction less
             than 50%;or history of following disease in past 6 months: acute coronary
             syndrome、acute heart failure、severe ventricular arrhythmia；

          -  Known sensitivity or allergy to investigational Product;

          -  Major surgery within three weeks;

          -  Presence of Grade III nervous toxicity within past two weeks;

          -  Active and severe infectious diseases;

          -  History of DVT or PE within past 12 months；

          -  Any potential drug abuse, medical, psychological or social conditions which may
             disturb this investigation and assessment;

          -  In any conditions which investigator considered ineligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, PhD&amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huayuan Zhu, PhD&amp; MD</last_name>
    <phone>86 25 68306034</phone>
    <email>huayuan.zhu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huayuan Zhu, PhD，MD</last_name>
      <phone>+86 68136034</phone>
      <email>huayuan.zhu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014 Jul;166(1):77-83. doi: 10.1111/bjh.12846. Epub 2014 Mar 25.</citation>
    <PMID>24661044</PMID>
  </reference>
  <reference>
    <citation>Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO). Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5.</citation>
    <PMID>26847165</PMID>
  </reference>
  <reference>
    <citation>Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29.</citation>
    <PMID>25267740</PMID>
  </reference>
  <reference>
    <citation>Shen QD, Zhu HY, Wang L, Fan L, Liang JH, Cao L, Wu W, Xia Y, Li JY, Xu W. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol. 2018 Jun;5(6):e261-e269. doi: 10.1016/S2352-3026(18)30054-1. Epub 2018 May 8.</citation>
    <PMID>29752199</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lenalidomide</keyword>
  <keyword>R-GOD</keyword>
  <keyword>DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

